As the spike protein of the SARS-CoV-2 envelope has been shown to be highly immunogenic and is the main target for neutralizing antibodies, the present pilot study aimed to evaluate the IgG antibody response to SARS-CoV-2 spike protein in HIV seropositive patients co-infected with COVID 19.
No takes yet. Share an insight, caveat, or question.
Rumpa et al. (2021) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: